Prelude Therapeutics Stock Market Value
| PRLD Stock | USD 2.12 0.09 4.43% |
| Symbol | Prelude |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Prelude Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prelude Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prelude Therapeutics.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Prelude Therapeutics on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Prelude Therapeutics or generate 0.0% return on investment in Prelude Therapeutics over 90 days. Prelude Therapeutics is related to or competes with Pyxis Oncology, Orchestra BioMed, Enanta Pharmaceuticals, Caribou Biosciences, Inventiva, Tenaya Therapeutics, and Avalo Therapeutics. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development... More
Prelude Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prelude Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prelude Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 13.63 | |||
| Information Ratio | 0.0869 | |||
| Maximum Drawdown | 206.09 | |||
| Value At Risk | (16.17) | |||
| Potential Upside | 16.44 |
Prelude Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prelude Therapeutics' standard deviation. In reality, there are many statistical measures that can use Prelude Therapeutics historical prices to predict the future Prelude Therapeutics' volatility.| Risk Adjusted Performance | 0.0762 | |||
| Jensen Alpha | 2.06 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.137 | |||
| Treynor Ratio | (1.15) |
Prelude Therapeutics January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0762 | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 9.37 | |||
| Semi Deviation | 11.48 | |||
| Downside Deviation | 13.63 | |||
| Coefficient Of Variation | 1102.89 | |||
| Standard Deviation | 21.49 | |||
| Variance | 461.82 | |||
| Information Ratio | 0.0869 | |||
| Jensen Alpha | 2.06 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.137 | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 206.09 | |||
| Value At Risk | (16.17) | |||
| Potential Upside | 16.44 | |||
| Downside Variance | 185.8 | |||
| Semi Variance | 131.81 | |||
| Expected Short fall | (10.59) | |||
| Skewness | 4.88 | |||
| Kurtosis | 36.16 |
Prelude Therapeutics Backtested Returns
Prelude Therapeutics is abnormally volatile given 3 months investment horizon. Prelude Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.1, which implies the firm had a 0.1 % return per unit of risk over the last 3 months. We were able to break down and interpolate thirty different technical indicators, which can help you to evaluate if expected returns of 2.23% are justified by taking the suggested risk. Use Prelude Therapeutics Risk Adjusted Performance of 0.0762, coefficient of variation of 1102.89, and Semi Deviation of 11.48 to evaluate company specific risk that cannot be diversified away. Prelude Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of -1.68, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Prelude Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Prelude Therapeutics is expected to outperform it. Use Prelude Therapeutics semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to analyze future returns on Prelude Therapeutics.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Prelude Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Prelude Therapeutics time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prelude Therapeutics price movement. The serial correlation of -0.17 indicates that over 17.0% of current Prelude Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | 0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Prelude Therapeutics Correlation, Prelude Therapeutics Volatility and Prelude Therapeutics Alpha and Beta module to complement your research on Prelude Therapeutics. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.